Non-traumatic rhabdomyolysis: The emerging role of CYP 3A4 in diabetes mellitus [5]

Journal of the Royal Society of Medicine

Volumn 99, Issue 8, 2006, Pages 385-386

  Varughese, George I ^a   Scarpello, John H B ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CLOPIDOGREL; COLCHICINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; PIOGLITAZONE; PRAVASTATIN; RITONAVIR; SIMVASTATIN;

DIABETES MELLITUS; DRUG EFFECT; GRAPE JUICE; HUMAN; INCIDENCE; LETTER; RHABDOMYOLYSIS; SYSTEMATIC REVIEW;

EID: 33748642997     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680609900808     Document Type: Letter

References (5)

1. Gangopadhyay KK, Ryder RE. Nontraumatic rhabdomyolysis: an unusual complication of diabetic hyperosmolar nonketotic (HONK) state. J R Soc Med 2006;99:200
2. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52-60
3. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006;40:753 -7
4. Roten L, Schoenenberger RA, Krahenbuhl S, Schlieriger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38:978-81
5. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-18